decided to renew the contracts with the projects that have appropriate gross profit margin only. Financial performance of management service for the nine-month period (Unit : Million Baht) 2017 2016 Change

No: AH 03052021 May 17, 2021 Subject: Management Discussion & Analysis (MD&A) for the financial statements of the 1st quarter of fiscal year 2021 ended as of March 31, 2021 To: The President The Stock

Committee, Appointment of Audit Committee, Appointment of Company Secretary, the Establishment of New Subsidiary and Subsidiary to Purchase Drug Care Company Limited (Revise no. 2) 10/11/2021 09:27

(Translation) Re: BOD.SET 008/2019 May 13, 2019 Subject: Clarification on the Change in operating results for the three month ended March 31, 2019 over 20% compared with the same period of the

(Translation) Re: BOD.SET 017/2018 August 10, 2018 Subject: Clarification on the Change in operating results for the three month period ended June 30, 2018 over 20% compared with the same period of

(Translation) Re: BOD.SET 020/2018 November 9, 2018 Subject: Clarification on the Change in operating results for the nine month ended September 30, 2018 over 20% compared with the same period of the

Microsoft Word - MDA Q219 EN August 14, 2019 To President The Stock Exchange of Thailand Subject Notification on the difference of revenue from sales and net profit YOY by more than 20 percent

วันที่ 15 ตุลาคม 2545 1 NO. (SUTHA-SET) 002/2020/EN 26 February 2020 Subject: Management Discussion and Analysis of the Company and its subsidiary for the year ended 31 December 2019 To: The

to the total revenue and total expenses for Q1–2018 and Q1–2017, it found that the change rate in total revenue which was 8.3%, was lower than the increase rate in cost which was 1.3% due to the gross

Company Limited and its subsidiaries (“the Company”) reported consolidated revenues of Baht 277.3 million, decreased by 42.3% compared to the same quarter last year, majorly due to the Covid-19 pandemic